The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s...read more
Aduro Biotech, which is developing an immunotherapy for pancreatic cancer, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering. 2014 immuno-oncology biotech IPOs have traded well, including Kite Pharma (KITE; +287%),...read more
Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T-cells, filed on Friday with the SEC to raise up to $115 million in an initial public offering. The company currently trades on the Alternext market of the Euronext Paris under...read more
Spark Therapeutics, which is developing gene therapy treatments for retinal dystrophies and hematologic disorders, announced terms for its IPO on Tuesday. The Philadelphia, PA-based company plans to raise $88 million by offering 5.5 million shares at a price...read more
Renaissance IPO Index - Notice of September 2015 Quarterly Changes
The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s...read more
Pancreatic cancer biotech Aduro files for a $86 million IPO
Aduro Biotech, which is developing an immunotherapy for pancreatic cancer, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering. 2014 immuno-oncology biotech IPOs have traded well, including Kite Pharma (KITE; +287%),...read more
Gene-edit the cancer out: Cellectis files for a $115 million US IPO
Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T-cells, filed on Friday with the SEC to raise up to $115 million in an initial public offering. The company currently trades on the Alternext market of the Euronext Paris under...read more
Gene therapy biotech Spark Therapeutics sets terms for $88 million IPO
Spark Therapeutics, which is developing gene therapy treatments for retinal dystrophies and hematologic disorders, announced terms for its IPO on Tuesday. The Philadelphia, PA-based company plans to raise $88 million by offering 5.5 million shares at a price...read more